Area of research
Infectious Diseases · Oncology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, PARP inhibition in cancer therapy, interferon and immune responses, and COVID-19 Clinical Research Studies.
Correction for Pfannenstiel et al., "Identification of a series of pyrrolo-pyrimidine based SARS-CoV-2 Mac1 inhibitors that repress coronavirus replication".
An autoimmunity-associated allele of <i>PTPN22</i> enhances innate antiviral immunity to protect against acute coronavirus infection.
SARS-CoV-2 and MERS-CoV disrupt host protein synthesis via nsp1 with differential effects on the integrated stress response.
PARP14 is an interferon-induced host factor that promotes IFN production and affects the replication of multiple viruses.
Identification of a series of pyrrolo-pyrimidine-based SARS-CoV-2 Mac1 inhibitors that repress coronavirus replication.
IFN-γ signaling is required for the efficient replication of murine hepatitis virus (MHV) strain JHM in the brains of infected mice.
Mutations differentially affecting the coronavirus Mac1 ADP-ribose binding and hydrolysis activities indicate that it promotes multiple stages of the viral replication cycle.
Mutations differentially affecting the coronavirus Mac1 ADP-ribose binding and hydrolysis activities indicate that it promotes multiple stages of the viral replication cycle
Quorum sensing regulation by the nitrogen phosphotransferase system in <i>Pseudomonas aeruginosa</i>.
SARS-CoV-2 nsp15 endoribonuclease antagonizes dsRNA-induced antiviral signaling.
Mutation of a highly conserved isoleucine residue in loop 2 of several β-coronavirus macrodomains indicates that enhanced ADP-ribose binding is detrimental for replication.
SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in cell culture and in mice.
PARP12 is required to repress the replication of a Mac1 mutant coronavirus in a cell- and tissue-specific manner.
An Update on the Current State of SARS-CoV-2 Mac1 Inhibitors.
Inhibitors of One or More Cellular Aurora Kinases Impair the Replication of Herpes Simplex Virus 1 and Other DNA and RNA Viruses with Diverse Genomes and Life Cycles.
Two Commercially Available Blood-Stabilization Reagents Serve as Potent Inactivators of Coronaviruses.
ADP-ribosyltransferases, an update on function and nomenclature.
MERS-CoV endoribonuclease and accessory proteins jointly evade host innate immunity during infection of lung and nasal epithelial cells
Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening.
The Conserved Macrodomain Is a Potential Therapeutic Target for Coronaviruses and Alphaviruses.
Design, synthesis and evaluation of inhibitors of the SARS-CoV-2 nsp3 macrodomain.
PARP14: A key ADP-ribosylating protein in host-virus interactions?
ADP‐ribosyltransferases, an update on function and nomenclature
The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase.
Unique Mutations in the Murine Hepatitis Virus Macrodomain Differentially Attenuate Virus Replication, Indicating Multiple Roles for the Macrodomain in Coronavirus Replication.
High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain
β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway
β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway.
The impact of PARPs and ADP-ribosylation on inflammation and host-pathogen interactions.
Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.